Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Decreased pre-surgical CD34 +/CD144 + cell number in patients undergoing coronary artery bypass grafting compared to coronary artery disease-free valvular patients

  • Redondo, Santiago
  • González-Rocafort, Álvaro
  • Navarro-Dorado, Jorge
  • Ramajo, Marta
  • Hristov, Mihail
  • Gordillo-Moscoso, Antonio
  • Reguillo, Fernando
  • Carnero-Alcázar, Manuel|||0000-0001-5045-5765
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Enrique
  • Weber, Christian
  • Tejerina, Teresa
Background: Cardiovascular disease has been linked to endothelial progenitor cell (EPC) depletion and functional impairment in atherosclerosis and aortic stenosis. EPCs may play a pivotal role in vascular grafting. However, the EPC depletion in coronary artery bypass grafting (CABG) patients has not been compared to coronary artery disease-free valvular replacement patients with aortic stenosis.Methods: We aimed to assess the basal number of CD34 /KDR and CD34 /CD144 cells in CABG patients, compared to aortic stenosis valvular replacement patients. 100 patients (51 CABG and 49 valvular surgery ones) were included in the present study. All CABG or valvular patients had angiographic demonstration of the presence or the absence of coronary artery disease, respectively. Numbers of CD34 /KDR and CD34 /CD144 were assessed by flow cytometry of pre-surgical blood samples.Results: We found a lower number of CD34 /CD144 cells in CABG patients compared to valvular patients (0.21 ± 0.03% vs. 0.47 ± 0.08%), and this difference remained statistically significant after the P was adjusted for multiple comparisons (P = 0.01428). Both groups had more EPCs than healthy controls.Conclusions: Pre-surgical CD34 /CD144 numbers are decreased in CABG patients, compared to valvular patients with absence of coronary disease. © 2012 Redondo et al; licensee BioMed Central Ltd.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Emerging therapeutic strategies to enhance HDL function

  • Redondo, Santiago
  • Martínez-González, José|||0000-0002-3894-7166
  • Urraca, C.
  • Tejerina, T.
Abstract. Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened new expectations in the treatment of CVD. © 2011 Redondo et al; licensee BioMed Central Ltd.